News

Abbott Laboratories (NYSE:ABT) delivered strong fiscal Q2 2026 results, beating quarterly estimates and raising its annual profit forecast as robust demand for its cancer diagnostics and medical devices businesses helped ease investor concerns surrounding procedure volumes. Sales for the quarter rose 13% on a reported basis and 4.8% on a comparable basis. Danaher Corporation’s (NYSE:DHR) […]

Abbott Laboratories, Taiwan Semiconductor, and Johnson & Johnson have all delivered strong earnings releases in the Q2 cycle, with each breaking records while also lifting their outlooks.

AllianceBernstein (NYSE:AB) reported record assets under management and its strongest quarterly sales in five years during the second quarter of 2026, as fixed-income demand, private-market deployments and insurance-related mandates helped the firm return to positive organic growth. Adjusted earnin

Jensen Investment Management, an asset management company based in the US, released its second-quarter 2026 investor letter for the “Jensen Quality Growth Equity Strategy”. A copy of the letter is available to download here. The fund seeks long-term growth by investing in high-quality companies with durable competitive advantages. It returned 10.94% net of fees in […]

ABT's earnings beat and higher profit outlook strengthen its case, but can growth in devices and diagnostics overcome valuation and acquisition concerns?

Companies raising guidance, particularly on the earnings front, always deserve some level of attention from investors. Recently, JNJ, GM, and ABT have all raised their outlooks.

Abbott Laboratories earnings put recent stock moves in context Abbott Laboratories (ABT) is back in focus after its latest quarterly earnings, where higher year over year sales came alongside lower net income and earnings per share, sharpening attention on upcoming estimates. See our latest analysis for Abbott Laboratories. After these earnings, Abbott Laboratories' recent rally stands out, with a 7 day share price return of 12.66% and a 30 day share price return of 14.51% contrasting with a...

BSX faces Q2 results with growth expected in key businesses, but lowered full-year guidance, cost pressures and weak stock performance cloud the outlook.

Charles River Laboratories is poised to announce its second-quarter results next month, and analysts predict a double-digit drop in the company’s bottom-line figure.

Abbott's raised 2026 earnings outlook and four growth drivers point to a faster second half across nutrition, devices, diagnostics and diabetes care.

Abbott Laboratories (ABT) reports robust sales growth and raises full-year EPS guidance, driven by strong performance in Nutrition, Medical Devices, and Emerging Markets.

US benchmark equity indexes were lower intraday amid a sell-off in certain chip-related stocks as in

Abbott Laboratories (NYSE:ABT) shares rose nearly 11% on Thursday after the healthcare company reported second quarter 2026 results that topped Wall Street expectations and raised its full-year adjusted earnings guidance. The company posted adjusted diluted earnings per share of $1.31 for the...

ABT tops Q2 earnings and revenue estimates and lifts 2026 EPS guidance, while Medical Devices and Cancer Diagnostics fuel growth despite Nutrition weakness.

The S&P 500 and Nasdaq Composite were down in late-morning trading Thursday, while the Dow Jones Ind

Abbott Laboratories (NYSE:ABT) reported second-quarter 2026 comparable sales growth of 4.8% and adjusted earnings per share of $1.31, with Chairman and Chief Executive Officer Robert Ford saying results marked an acceleration from the prior two quarters. The company reaffirmed its full-year compara

Abbott Laboratories (ABT) lifted its full-year earnings outlook on Thursday as the healthcare firm r

Although the revenue and EPS for Abbott (ABT) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

The healthcare company posted adjusted earnings of $1.31 a share in the second quarter, topping Wall Street's estimate of $1.28

Abbott Laboratories (NYSE:ABT) delivered stronger-than-expected second-quarter results and increased its full-year earnings guidance, sending its shares about 2. 5% higher in premarket trading.

Abbott (ABT) delivered earnings and revenue surprises of +2.34% and +0.91%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Investing.com -- Abbott (NYSE:ABT) shares are trading higher premarket on Thursday after the company reported second-quarter earnings, topping consensus expectations and raising its full-year earnings guidance.

US equity markets were mostly tracking in the red before the opening bell Thursday as traders await

ABT heads into Q2 earnings results with growth expected across Diagnostics, Devices and EPD, while Nutrition remains a drag. Here's what could shape the results.

Abbott Laboratories (ABT) is back in focus after reporting Q1 2026 sales of US$11.16b with solid contributions from Medical Devices and issuing full year guidance that points to mid single digit comparable sales growth. See our latest analysis for Abbott Laboratories. Abbott Laboratories shares have picked up short term momentum, with a 7 day share price return of 5.62% and a 30 day share price return of 5.24%. This sits against a year to date share price decline of 22.83% and a 1 year total...

Earnings results often indicate what direction a company will take in the months ahead. With Q1 behind us, let’s have a look at AbbVie (NYSE:ABBV) and its peers.

Abbott Laboratories is scheduled to report its second-quarter results in July, and analysts expect a single-digit earnings rise.

The medical device maker posts fiscal fourth-quarter earnings and revenue that narrowly beat analysts’ estimates.

Investors weigh softer WATCHMAN and urology demand against a still-active device pipeline and capital deployment moves, today, May 27, 2026.

ABT's Q1 beat was overshadowed by Exact Sciences dilution, legal risks and weak Diagnostics trends as shares hit a 52-week low.